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The novel severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2)world-
wide pandemic has been devastating
particularly for older adults and those
from vulnerable groups, including racial
and ethnic minority populations. Addi-
tionally, people with certain underlying
medical conditions, including diabetes,
are also at increased risk of severe illness
from coronavirus disease 2019 (COVID-
19) (1,2). Some children experience sig-
nificant disease (3), and pediatric deaths
have been reported (4). Because “diabe-
tes” (generally grouping together type 1
diabetes and type 2 diabetes) and chron-
ically elevated hyperglycemia have been
associatedwith worse outcomes in adults
with COVID-19 (5), the pediatric commu-
nity has voiced great concerns about risk
and outcomes for children with diabetes.
A foundation of pediatrics is caution
about the extrapolation of adult practice
to children. Many publications report
poor outcomes from COVID-19 and di-
abetes without emphasizing that data
reported are fromadults, frequently older
adults with additional comorbidities.
Moreover, there have been warnings re-
lated to COVID-19 and immunosuppres-
sion leading to confusion, predominately
outside the medical community, about
the difference between immunocompro-
mised and autoimmune. In sum, these
worries have led to increases in frequency
and severity of diabetic ketoacidosis
(DKA), due in part to families being
reluctant to enter health care settings,
especially in areas where COVID-19
cases cluster (6,7).
Data scarcity regarding many aspects
of how COVID-19 is affecting children
with both new-onset and established
diabetes has magnified these concerns.
In this issue of Diabetes Care, Rabbone
et al. (8) describe cross-sectional data
from Italy, an early pandemic epicenter.
This team examined diabetes diagnoses
aswell as reports of DKA and SARS-CoV-2
infection in children with new-onset and
established type 1 diabetes from 20 Feb-
ruary to 14 April 2020. They compare
data onnewpresentations andDKA rates
to data from the same period in 2019.
They report 23% fewer new-onset cases
during this time, withmore children with
new-onset disease presenting in DKA;
they speculate that the observed decrease
maybedueto fearofpresentation tohealth
care facilities, implying that observed rates
might rebound in a subsequentobservation
period. They also note that differences in
exposure to other seasonal viruses associ-
ated with precipitating type 1 diabetes
might have affected presentation rates.
Two additional reports in this issue
also address whether SARS-CoV-2 infec-
tion affected new pediatric type 1 diabe-
tes diagnosis rates (9,10). Interestingly,
one posits an increase and the other
documents no change. Unsworth et al.
(9) report data from five U.K. regional
inpatient units collected from late March
to early June 2020. One of the five units
reported an increase from two to ten
cases, and a second reported an increase
from four to ten cases; the other three
units reported no change. Like Rabbone’s
report, many of the newly diagnosed
children had severe DKA. The U.K. group
states that these data point to an increase
in incidenceofpediatric type1diabetes of
up to 80%. However, the report does not
provide information on the total denom-
inator of unit or hospital admissions,
typical variability in case numbers,
whether this increase is statistically sig-
nificant over time, or how many newly
diagnosed children regionally are typically
treated at these hospitals versus other
area facilities. The authors then theorize
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that a higher type 1 diabetes incidence
could be related to SARS-CoV-2 infection
of the pancreas and cite data showing
angiotensin converting enzyme 2 (ACE2)
receptor expression in b-cells from a
2010 article by Yang et al. (11). However,
this assertion is based on immunofluo-
rescence analysis of a single organ donor
with limited methodologic details pro-
vided regarding reagent validation or
even antibody source. Thus, at present,
the presence and the level of ACE2 ex-
pression in b-cells remains controversial.
Moreover, analysis of pancreata from
individuals infected with SARS-CoV-2 is
not available to support the notion of
direct b-cell infection Additionally, rapid
viral-mediated increases in incidence
are not very plausible, as fulminant
autoimmune-mediated diabetes does not
acutely present after infection. Rather, ex-
posures to viruses that may trigger type 1
diabetesgenerallypredateclinicalonsetsby
months to years (12). The higher incidence
rates observed in two regional inpatient
units are more likely due to other factors.
In contrast, Tittel et al. (10) exam-
ined country-wide electronic medical re-
cord data from the Diabetes-Prospective
Follow-up registry (DPV). Based on
population-level data from 216 of 217
DPV clinics, the rate of new-onset pedi-
atric type 1 diabetes observed across
Germany from mid-March to mid-May
2020 did not differ significantly from
predicted rates based on data collected
over the last decade. Taken in sum, these
three articles do not provide compelling
evidence that the pandemic is leading to
dramatic short-term adverse changes in
incidence of pediatric type 1 diabetes.
Changes in viral exposure, including novel
exposures to SARS-CoV-2 and fewer ex-
posures to normally prevalent pediatric
communicable diseases due to public
health mitigation measures, could poten-
tially shift future incidence rates and
observed diabetes endotypes.
These articles also provide reassuring
information regarding acute COVID-19
morbidity. Rabbone et al. reported on
eight children with PCR-confirmed SARS-
CoV-2, all of whom had mild disease or
were asymptomatic, although they did
not provide a population estimate of
infection in children with type 1 diabetes
or how this compares to peers without
diabetes. Unsworth et al. included five
childrenwith evidence of current or prior
SARS-CoV-2 infection by PCR or antibody
testing; none had long-term adverse
COVID-19–related outcomes.
Overall, the accumulating evidence
suggests that children with type 1 di-
abetes infected with SARS-CoV-2 will
have similar disease outcomes as peers
without diabetes. In particular, the ar-
ticle by Rabbone et al. reflects obser-
vations using longitudinal, prospectively
collected data from a country that was
an early pandemic epicenter, with co-
ordinated national health and insurance
programs and a high underlying type 1
diabetes population prevalence. Addi-
tionally, the physicians reporting the
data were embedded early in the health
care provider response to COVID-19.
Since their findings reflect only one
country’s experience during a snapshot
in time, the data need to be placed in
context with other emerging reports.
Routine surveillance data collection
made these articles possible. As we are
seeing more documented pediatric SARS-
CoV-2 infections (4), providers need to
ensure that the documentation of patient-
level data in electronic health records
continues for our children with diabetes
as wemonitor for both acute and longer-
term disease-related morbidities. Such
efforts are underway in Germany and
Austria through the DPV and in the U.S.
through the T1D Exchange (13).
It is important to remember that these
articles only report data from children
with type 1 diabetes. Given that obesity
andhypertension are associated strongly
with type 2 diabetes in youth and these
comorbidities have been associated with
more severe COVID-19 cases (14), chil-
dren with type 2 diabetes may be at
higher risk. Country-wide surveillance
and reporting systems need to be im-
plemented for children with type 2
diabetes.
The COVID-19 pandemic and related
changes in daily life are complicating the
already complex demands of blood glu-
cose management for youth with diabe-
tes. Countries have instituted aggressive
public health measures, implementing
widespread closures and other dramatic
structural school, day care, and camp
changes (15,16). Despite these changes,
there have been reports of rapid and
widespread disease dissemination in set-
tings where children cluster with even
asymptomatic children spreading the
virus to other children aswell as to adults
(17,18).
As we write, parents and children are
making difficult decisions about return-
ing to school. These decisions impact the
safety of not only children with diabetes
but also those who live with them. It is
critical that we work together to make
sure that our children are safe at school
(19). This includes following Centers
for Disease Control and Prevention and
other guidelines on the appropriateness
of regional school reopenings, appropri-
ate classroom distancing, use of face
coverings, and cleaning procedures.
Each decision about returning to school
needs to be contextualized and individ-
ualized. Formany childrenwith diabetes,
schools are a public health lifeline for
diabetes care, daily health surveillance,
and adequate nutrition.
The pandemic has had a great emo-
tional impact. As Tittel et al. point out,
stress may influence rates of new-onset
disease by changing the risk of develop-
ing autoimmunity (20). Additionally, for
persons with established disease, mental
health symptoms coupledwith decreased
physical activity, dietary changes leading
to poorer nutrition and weight gain, and
sleep disruptions (21–23) may alter di-
abetesmanagement behaviors and promote
diabetes conflict.Moreover, individualswith
higher levels of worry about COVID-19 and
diabetes may be more vulnerable for di-
abetes distress, acute and chronic hypergly-
cemia, and the onset or exacerbation of
depression and anxiety (24).
Children with diabetes are also reliant
on expensive medications (including in-
sulin), glucose monitoring, and insulin
delivery technologies. The pandemic has
caused some supply chain disruptions,
including a shortage of metformin, and
exacerbated insurance and copay con-
cerns for many, which may increase
existing disparities in diabetes care for
youth (25). We need to continue to
encourage and increase national pediat-
ric access to continuous glucose moni-
toring systems to facilitate glycemic
monitoring and data sharing with care
teams and remote monitoring by school
staff and other caregivers.
Since March 2020, there has been an
increase in diabetes health care visits
conducted via telemedicine. Although
providers have had successes, there
have also been difficulties collecting suf-
ficient data for effective assessments to
facilitate insulin adjustments and be-
havioral advice. Lack of internet and
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hardware access, particularly for children
living in lower socioeconomic settings
and non-English speakers, has also ham-
pered access to multidisciplinary diabe-
tes care.
While we await more high-quality
data, clinical providers need to consider
how often children with diabetes need to
be seen in person and what can be ac-
complished virtually. Although some chil-
drenmaydobetterunder lockdowndue to
more time to focus on self-management
(26), others will require additional touch-
points. These may be especially critical for
children at risk for or experiencing the
economic consequences of COVID-19 in-
cluding evictions and homelessness. Pro-
viders should accommodate and engage
patients with limited technology and in-
ternet access. Hospital systems should
prioritize telehealth for conditions such
as diabetes. Payors also need to offer
clearly durable telemedicine coverage that
includes adequate payment structures
given that virtual visits for children with
diabetes, to be done properly, require
multidisciplinary interactions, intensive of-
fice staff support, and the ability to obtain
glycemic data and laboratory results re-
motely. It will also be critical that our
children with diabetes continue to receive
holistic care and remain current on immu-
nizations, particularly influenza.
We are in a place where the only
certainty is continued uncertainty about
the course of this pandemic. We thank
our international pediatric diabetes
colleagues and hope their work spurs
others to collaborate internationally to
gather more evidence (27). We call on
our community to articulate needs and
refine recommended actions (Table 1).
As federal diabetes funding is uncertain
and many not-for-profit organizations,
including the American Diabetes Associ-
ation and JDRF, announce cuts in funding
opportunities and staffing, we must gal-
vanize the pediatric diabetes volunteer
community (28,29) to joinourefforts.We
must continue to be humble and patient
aboutwhatweknowandadvocate stren-
uously for coordinated, expanded, and
responsive public health systems to sup-
port youth with both type 1 and type 2
diabetes.
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